Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 269

Developing novel combination therapies for diffuse intrinsic pontine glioma

This project will develop novel combination therapies for the most aggressive childhood cancer, diffuse intrinsic pontine glioma (DIPG). Our team performed a comprehensive high-throughput drug screen, testing 3,570 drugs for their ability to prevent DIPG cell growth and found ACT001 to be one of the most effective drugs tested. ACT001 is ...

TRANSLATING MECHANISM TO PATIENT BENEFIT FOR ACVR1-MUTANT DIFFUSE INTRINSIC ...

Diffuse intrinsic pontine glioma, or DIPG, is a childhood brain tumor occuring in the brainstem of young children, for which there is currently no cure. Until recently, little was known about the makeup of this type of cancer, and treatments used for other adult brain tumor types consistently failed. Through ...

Discovering novel epigenetic dependencies in Diffuse Intrinsic Pontine Glioma

 Scientific Merit  Recent genetic analyses have revealed specific and unique K27M mutations in the histone 3.3 side chain in more than 90% of DIPG cases.  Post-translational modifications of this histone 3.3 side chain are normally used as a “histone code” for fine-tuning gene expression across the whole ...

Elucidation of regional differences of ONC201 Response in H3K27...

Diffuse intrinsic pontine glioma (DIPG), recently renamed diffuse midline glioma (DMG), is an extremely aggressive and lethal pediatric brain tumor with no proven therapies beyond standard radiation. As such, few children with this diagnosis survive beyond 2 years, highlighting the dire need to identify and investigate novel genetic therapeutic targets in ...

EPIGENETIC ALTERATIONS AS THERAPEUTIC TARGETS IN PEDIATRIC BRAIN TUMORS

We and others co-discovered the presence of activating mutations in ACVR1 in 25% of human DIPGs in 2014. Subsequently, my laboratory has developed a murine DIPG model incorporating R206H ACVR1 and observed that R206H ACVR1 significantly accelerates brainstem gliomagenesis. In addition, short-term treatment with a bone morphogenetic protein pathway inhibitor (...

Identifying oncolytic viral therapy resistance mechanisms in brain tumors

Current adjuvant therapy for the malignant brain tumors medulloblastoma (MB) and pediatric high grade glioma (HGG) is marginally effective and often toxic. With standard chemotherapy and radiation, the 5-year overall survival (OS) of MB is 50-80%, however, nearly all patients experience lifelong neurocognitive and endocrine morbidity. The median OS of ...